Synaptogenix Inc. (NASDAQ: SNPX) has announced a peer-reviewed scientific publication in the Journal of Alzheimer’s Disease entitled, “Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer’s Disease (“AD”) in the Absence of Memantine.” Bryostatin-1 enhanced cognition in advanced Alzheimer’s Disease patients in two placebo-controlled studies, according to the article.
Peer-reviewed data supports the continued study of Bryostatin
In the absence of the dementia therapy memantine, robust statistical analysis, including pooled assessment of similar pre-specified cohorts in two different studies, demonstrated a highly significant (p.001) effect of Bryostatin-1 therapy of AD patients. In addition, the use of blinded placebo control in the studies eliminates the placebo impacts that frequently follow initial testing of potential medications to treat Alzheimer’s disease.
Daniel Alkon, Chief Scientific Officer and President, said, “Importantly, we believe that the peer-reviewed data in our manuscript has provided additional justification for our continued grant support from the National Institutes of Health (“NIH”) for our ongoing Phase 2b clinical trial.”
The company’s CEO Alan Tuchman, commented, “The power of these results, enhanced by appropriate pooling of pre-specified cohorts, provides encouragement that our six-month trial will confirm Bryostatin-1’s effective treatment of the underlying degenerative progression of AD – a claim that other therapeutic strategies have struggled to demonstrate to date.”
Synaptogenix developing Bryostatin-1 for Alzheimer’s disease
The company is focused on creating a therapeutic novel treatment for patients with developmental disorders and neurodegenerative diseases. Synaptogenix is now undertaking a Phase 2b drug study of their principal treatment product, Bryostatin-1, in moderate to severe Alzheimer’s disease patients, which the National Institutes of Health funds. In addition, Bryostatin-1’s regenerative modes of action have been proven in preclinical research for the rare disorder Fragile X syndrome. The Food and Drug Administration has awarded the drug Orphan Drug Designation for the treatment of Alzheimer’s disease. Stroke, Multiple sclerosis (“MS”), and traumatic brain damage are all possible indications that Byostrtatin can treat. More than 1,500 patients have been tested for Bryostatin in cancer research, resulting in a comprehensive safety registry that will benefit clinical trial designers.
